Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine in Severe Traumatic Brain Injury
NCT06062628Phase 1Withdrawn
- Sponsor
- UT Southwestern Medical Center
- Start
- Jun 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of ketamine in traumatic brain injury (TBI), sponsored by UT Southwestern Medical Center. Primary endpoints: Intracranial Pressure at 3 hours and Brain tissue oxygenation at 3 hours. Planned start Jun 2026; status: withdrawn.
02
Drugs
ketamine
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06062628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062628.